Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selecting a thrombolytic agent

H D White1

  • 1Department of Coronary Care and Cardiovascular Research, Green Lane Hospital, Auckland, New Zealand.

Cardiology Clinics
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Streptokinase is a cost-effective thrombolytic therapy for select patients, while accelerated tissue plasminogen activator (TPA) is preferred for high-risk individuals. Early administration of any thrombolytic agent is crucial for saving lives.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Common genetic variants do not predict recurrent events in coronary heart disease patients.

BMC cardiovascular disorders·2022
Same author

Excessive daytime sleepiness, morning tiredness and major adverse cardiovascular events in patients with chronic coronary syndrome.

Journal of internal medicine·2021
Same author

Psychosocial stress and major cardiovascular events in patients with stable coronary heart disease.

Journal of internal medicine·2017
Same author

UK service level audit of insulin pump therapy in paediatrics.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same author

The U.K. service level audit of insulin pump therapy in adults.

Diabetic medicine : a journal of the British Diabetic Association·2013
Same author

Effect of oral phosphate and alendronate on bone mineral density when given as adjunctive therapy to growth hormone replacement in adult growth hormone deficiency.

The Journal of clinical endocrinology and metabolism·2011
Same journal

At the Edge of the Possible: A New Standard for Cardiovascular Critical Care.

Cardiology clinics·2026
Same journal

End-of-Life Care in the Cardiovascular Intensive Care Unit.

Cardiology clinics·2026
Same journal

Strategies to Reduce Failure to Rescue after Cardiac Surgery.

Cardiology clinics·2026
Same journal

Embracing Enhanced Recovery After Cardiac Surgery Program.

Cardiology clinics·2026
Same journal

Post-Heart Transplantation Intensive Care Unit Recovery: A Phase-Based Approach.

Cardiology clinics·2026
Same journal

A Practical Guide to Intensive Care Unit Management after Left Ventricular Assist Device Implantation.

Cardiology clinics·2026
See all related articles

Area of Science:

  • Cardiology
  • Emergency Medicine
  • Pharmacology

Background:

  • Streptokinase is the most utilized thrombolytic agent globally due to its affordability.
  • Cost-effectiveness is a significant factor in treatment decisions, particularly when accelerated tissue plasminogen activator (TPA) exceeds a certain cost threshold per life year gained.
  • Iatrogenic stroke is a serious concern, influencing the selection of thrombolytic agents in patients with favorable prognoses.

Purpose of the Study:

  • To delineate the appropriate use cases for streptokinase versus accelerated TPA in thrombolytic therapy.
  • To highlight the importance of early intervention and patient presentation in optimizing outcomes for acute myocardial infarction.
  • To address the underutilization of thrombolytic therapy and advocate for increased patient access.

Main Methods:

Related Experiment Videos

  • Comparative analysis of streptokinase and accelerated TPA based on patient risk factors, infarct size, age, and time to treatment.
  • Review of clinical guidelines and cost-benefit considerations for thrombolytic agent selection.
  • Emphasis on process improvement, including "door-to-needle" times and patient education for early presentation.

Main Results:

  • Streptokinase is indicated for patients with small to moderate infarctions, those under 60, at increased stroke risk, presenting after 6 hours, or with cardiogenic shock.
  • Accelerated TPA is the preferred treatment for high-risk patients, including those with large anterior infarctions, the elderly, and those with bypass grafts.
  • Early thrombolytic therapy, irrespective of the agent, significantly improves patient survival rates.

Conclusions:

  • Treatment decisions for thrombolytic therapy should balance efficacy, cost, and patient-specific risk factors.
  • Optimizing "door-to-needle" times and encouraging prompt patient presentation are critical for maximizing the benefits of thrombolytic therapy.
  • Increased utilization of thrombolytic therapy holds the potential to save thousands of lives worldwide.